SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (504)7/27/1999 3:29:00 PM
From: Vector1  Read Replies (1) of 3158
 

CAMBRIDGE, Mass. (Dow Jones)--Genzyme General (GENZ) acquired Peptimmune
Inc., a privately held Massachusetts biotechnology company.
Financial terms weren't disclosed.
In a press release Tuesday, Genzyme said Peptimmune develops therapies for
inherited autoimmune disorders. Peptimmune's lead program is developing a
treatment for the genetic disease pemphigus vulgaris.
Genzyme develops and markets therapeutic products and diagnostic products
and services.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News